TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 8 in Percentage of Yes Responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Question 3 of the Patient Sexual Encounter Profile (SEP) Diary at Week 8 in Percentage of Yes Responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endoscopic Healing Rate of Gastric Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Procedure-related Acute Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Seroprotection Status for Anti-diphteria Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Cyclosporine in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change in EASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-t)) for single doses of ACT-453859
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) for single doses of ACT-453859
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma half life (t1/2) for single doses of ACT-453859
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean daily prednisone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histomorphometric analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall efficacy of enema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quadriceps muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in diameter of single fibre contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in peak aerobic power (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD-RS-IV Total Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Acute Respiratory Infections (ARIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: view of the tympanic membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: complete ulcer closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Trough Concentration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC [0-Last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients developing febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adolescent substance use initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint incidence of deep vein thromboembolism or pulmonary thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Perfusion outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mathematical attainment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Platelet reactivity unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Retinal and Choroidal Blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: knee movement assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Responders at Week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma level of Catestatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of routine cancer consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of routine cancer consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Content of routine cancer consultations
Endpoint domain: Delivery of care
Primary endpoint: Behavior Rating Inventory of Executive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: C11 Methionine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise in Mental Illness Questionnaire (EMIQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abdominal Muscle Thickness Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tube durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) Throughout Study
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Decayed Surfaces (DS) of Different Fissure Sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Repaired Sealants by the baseline ICDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DIAGNOdent Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premature ovarian failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline Symptoms at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Quality-of-Life at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline PET/CT scan at 18 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of concordance in the MRD assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duodenal histology (Marsh classification)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rectal histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of child wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Change in ALT (liver transaminases) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in score of fatty liver in fibroscan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Differences in bevacizumab responses as shown by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor, node, metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Delta change of dermal microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta change of endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK1265744 area under the concentration-time curve for 12 weeks (AUC 0-wk12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK1265744 last observed quantifiable concentration at week 12 (Cwk12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK1265744 maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the levels of TXB2 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in the levels of 12-HETE in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anatomic failure to correct apical POP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Periodontal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fistula Maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PASI score at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor apoptosis as measured by annexin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Advance care planning completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post injection Oxford Shoulder Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: IL-6 and IL-8 levels 2 hours post CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extra vascular lung water 2 and 24 hours post CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Presence of a Sun Protection Policy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Local Anesthetic Received Through PCEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in LDL-C (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in sitting systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in subjective evaluation of botulinum toxin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in objective evaluation of botulinum toxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Low Disease Activity (LDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days Engaged in Vigorous Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self Efficacy for Practicing Good Dietary Habits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentrations of volatile biomarkers in breath samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improved ability to function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: marijuana abuse/dependence symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on the Functional Mobility Assessment Tool
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with seizure-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Asymmetric dimethylarginine (ADMA) blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in High-sensitivity C-reactive protein (HsCRP) blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in soluble CD40 Ligand (sCD40L) blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in urine 8-isoprostane-F2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in albumine to creatine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ulnar-Hypothenar CMAP Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ulnar-Hypothenar CMAP Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median-Thenar CMAP Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median-Thenar CMAP Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peroneal-EDB CMAP Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FEV1 AUCbl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bronchial responsiveness to methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C13 Leucine incorporation in Amyloid peptides (1-40, 1-42)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C13 Leucine incorporation in detectable peptides from biological fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of AUC0-24(PM)/AUC0-24(EM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema evaluation using Facial measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trismus Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular End-Systolic Volume Index (LVESVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sexual Encounter Profile SEP2 and SEP3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of intrathecal administration of Neuro-Cells
Endpoint domain: Adverse events/effects
Primary endpoint: Statin prescription at hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Goals and expectations towards spinal cord stimulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients With Total Testosterone Within Normal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Collaboration and Satisfaction Survey About Care Decisions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Without Virologic Failure at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Constant-Murray Shoulder score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: American Shoulder and Elbow Surgeon score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: University of California-Los Angeles score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of early rehabilitation and/or mobilisation delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red cell transfusion independency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving a mRS of 0 to 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurocognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in memory functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in general cognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in attention functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Intelligence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immunohistochemistry scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of unnecessary biopsies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of diabetic retinopathy risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with virologic suppression to less than 500 copies/ml at 34 weeks gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with virologic suppression to less than 500 copies/ml at 48 weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) last of Evogliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of malnourished patients or at risk of malnourishment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients who needed specialized nutritional care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the Weekly Mean Pain Index Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of participants with access to physiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants that use physiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants' perceived efficacy of physiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Curve of plasma levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Concentration of plasma levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of in-hospital acute renal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cervical dentin hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cog-Awareness ADL Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Renal Function Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary albumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite of all fatal or non-fatal strokes or non CNS systemic embolic events
Endpoint domain: Mortality/survival
Primary endpoint: muscle strength of extremity muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue perception
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: respiratory functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of microvascular invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Molecular Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nipple Sensation Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Receptive One-Word Picture Vocabulary Test (ROWPVT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on Dimensional Change Card Sort (DCCS) Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on Pencil Tap Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on Parental Engagement of Families Questionnaire (PEFL)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cmax of multiple administration of rh-Tβ4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative EEG (qEEG) features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of EFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in logCFU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in time-to-positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tolerability based on cutaneous tolerability scores
Endpoint domain: Adverse events/effects
Primary endpoint: Rate and time of entering the critical stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Cortical Silent Period (CSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in threshold for eating uncooked apple
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of post-ERCP pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes